GSK-3α directly regulates β-adrenergic signaling and the response of the heart to hemodynamic stress in mice

Journal of Clinical Investigation

Volumn 120, Issue 7, 2010, Pages 2280-2291

  Zhou, Jibin ^a   Lal, Hind ^a   Chen, Xiongwen ^b   Shang, Xiying ^a   Song, Jianliang ^a   Li, Yingxin ^b   Kerkela, Risto ^a   Doble, Bradley W ^c   MacAulay, Katrina ^d   DeCaul, Morgan ^a   Koch, Walter J ^a   Farber, John ^a   Woodgett, James ^d   Gao, Erhe ^a   Force, Thomas ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; CYCLIC AMP; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; ISOPRENALINE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; ADRENERGIC RECEPTOR STIMULATING AGENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 ALPHA; GLYCOGEN SYNTHASE KINASE 3 BETA; ISOPROTEIN; NORADRENALIN; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE TARGETING; HEART LEFT VENTRICLE PRESSURE; HEART MITOCHONDRION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC STRESS; IMMUNOBLOTTING; KNOCKOUT MOUSE; MORPHOMETRICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WILD TYPE; ANIMAL; CARDIOMEGALY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEART; HEART MUSCLE CELL; HEMODYNAMICS; HYPERTROPHY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ADRENERGIC AGENTS; ANIMALS; CARDIOMEGALY; GLYCOGEN SYNTHASE KINASE 3; HEART; HEMODYNAMICS; HYPERTROPHY; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; NOREPINEPHRINE; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 77954966442     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI41407     Document Type: Article

References (43)

1. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003;116(pt 7):1175-1186.
2. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol. 2009;156(6):885-898.
3. Force T, Woodgett JR. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem. 2009;284(15):9643-9647.
4. Ruel L, Bourouis M, Heitzler P, Pantesco V, Simpson P. Drosophila shaggy kinase and rat glycogen synthase kinase-3 have conserved activities and act downstream of Notch. Nature. 1993;362(6420):557-560.
5. Siegel JN, Klausner RD, Rapp UR, Samelson LE. T cell antigen receptor engagement stimulates craf phosphorylation and induces c-raf associated kinase activity via a protein kinase C-dependent pathway. J Biol Chem. 1990;265(30):18472-18480.
6. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell. 2007;12(6):957-971.
7. Kerkela R, et al. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest. 2008;118(11):3609-3618.
8. Antos CL, et al. Activated glycogen synthase kinase-3β suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2002;99(2):907-912.
9. Michael A, et al. Glycogen synthase kinase-3β regulates growth, calcium homeostasis, and diastolic function in the heart. J Biol Chem. 2004;279(20):21383-21393.
10. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res. 2003;92(6):609-616.
11. Trivedi CM, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3beta activity. Nat Med. 2007;13(3):324-331.
12. Hirotani S, et al. Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res. 2007;101(11):1164-1174.
13. Matsuda T, et al. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc Natl Acad Sci U S A. 2008;105(52):20900-20905.
14. Zhai P, et al. Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J Biol Chem. 2007;282(45):33181-33191.
15. Bikkavilli RK, Feigin ME, Malbon CC. p38 mitogen-activated protein kinase regulates canonical Wntbeta-catenin signaling by inactivation of GSK3beta. J Cell Sci. 2008;121(pt 21):3598-3607.
16. Thornton TM, et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science. 2008;320(5876):667-670.
17. McManus EJ, et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signaling defined by knockin analysis. EMBO J. 2005;24(8):1571-1583.
18. Patel S, Doble BW, MacAulay K, Sinclair EM, Drucker DJ, Woodgett JR. Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol. 2008;28(20):6314-6328.
19. Tanabe K, et al. Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol. 2008;6(2):e37.
20. MacAulay K, et al. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab. 2007;6(4):329-337.
21. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis. 2000;26(2):99-109.
22. Arad M, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352(4):362-372.
23. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17(6):596-603.
24. Sanbe A, Takeo S. Effects of NKH477, a water-soluble forskolin derivative, on cardiac function in rats with chronic heart failure after myocardial infarction. J Pharmacol Exp Ther. 1995;274(1):120-126.
25. Das S, Wong R, Rajapakse N, Murphy E, Steenbergen C. Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res. 2008;103(9):983-991.
26. Peineau S, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron. 2007;53(5):703-717.
27. Patel PA, Tilley DG, Rockman HA. Physiologic and cardiac roles of beta-arrestins. J Mol Cell Cardiol. 2009;46(3):300-308.
28. Patel PA, Tilley DG, Rockman HA. Beta-arrestin-mediated signaling in the heart. Circ J. 2008;72(11):1725-1729.
29. Sugden PH, Fuller SJ, Weiss SC, Clerk A. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol. 2008;153 suppl 1:S137-S153.
30. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412(2):179-190.
31. Inoki K, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126(5):955-968.
32. Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, Heidenreich KA. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol Cell Biol. 2000;20(24):9356-9363.
33. Taurin S, Hogarth K, Sandbo N, Yau DM, Dulin NO. Gbetagamma-mediated prostacyclin production and cAMP-dependent protein kinase activation by endothelin-1 promotes vascular smooth muscle cell hypertrophy through inhibition of glycogen synthase kinase-3. J Biol Chem. 2007;282(27):19518-19525.
34. Rowe MK, Wiest C, Chuang DM. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev. 2007;31(6):920-931.
35. Murphy E, Steenbergen C. Does inhibition of glycogen synthase kinase protect in mice? Circ Res. 2008;103(3):226-228.
36. Klapholz M. Beta-blocker use for the stages of heart failure. Mayo Clin Proc. 2009;84(8):718-729.
37. Chen X, et al. Ca2+ influx-induced sarcoplasmic reticulum Ca2+ overload causes mitochondrial-dependent apoptosis in ventricular myocytes. Circ Res. 2005;97(10):1009-1017.
38. Chen X, et al. Reduced effects of BAY K 8644 on L-type Ca2+ current in failing human cardiac myocytes are related to abnormal adrenergic regulation. Am J Physiol Heart Circ Physiol. 2008;294(5):H2257-H2267.
39. Chen X, et al. The β-catenin/T-cell factor/Lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy. Mol Cell Biol. 2006;26(12):4462-4473.
40. Jaleel N, et al. Ca2+ influx through T- and L-type Ca2+ channels have different effects on myocyte contractility and induce unique cardiac phenotypes. Circ Res. 2008;103(10):1109-1119.
41. Kerkela R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908-916.
42. Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, Koch WJ. Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol. 2007;293(1):H60-H68.
43. Chu T, et al. Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011-2019.